Lupin Launches Strategic Program to Enhance Long-Acting Injectable Platform Reach

Lupin Limited's Strategic Partnership Program

In an exciting development for the pharmaceutical industry, Lupin Limited, a prominent global pharmaceutical company headquartered in Mumbai, India, recently unveiled a strategic partnership program aimed at broadening the reach of its advanced drug delivery platform, PrecisionSphere™. Announced on October 9, 2025, this initiative comes on the heels of the recent approval of the first pharmaceutical product developed using this innovative long-acting injectable (LAI) platform by the U.S. Food and Drug Administration (FDA).

What is PrecisionSphere™?

PrecisionSphere™ is Lupin's cutting-edge platform for long-acting injectables designed to improve the efficacy and safety of drug administration. It demonstrates significant potential for enhancing patient compliance thanks to a formula that extends release periods of medications, allowing for less frequent injections. This advancement not only eases the burden on patients but also addresses critical challenges in the pharmaceutical manufacturing process, particularly those leading to revenue losses from non-compliance.

The Need for Collaboration

The program aims to foster collaborations with other pharmaceutical companies that are interested in leveraging their product portfolios—with an emphasis on those in development or already on the market. This collaboration is particularly vital for companies looking to enhance their product lifecycle through advanced formulations that align with the growing demand for long-acting therapies.

Dr. Fabrice Egros, Lupin’s Corporate Development President, expressed confidence in the company’s strategic capabilities, stating, "With the validation of the PrecisionSphere capabilities and our proven track record of executing strategic partnerships, we aim to enhance patient access to advanced LAI treatments through new global collaborations."

Enhancing Drug Manufacturing Processes

The PrecisionSphere™ platform stands out from traditional LAI technologies. Unlike conventional methods that result in variable particle sizes, this innovative platform allows for the consistent manufacture of drugs, ensuring uniform particle size, shape, and biological properties which enhance injectability. This consistency is crucial in optimizing drug release levels, allowing for a steady concentration throughout the treatment period, which can extend from weeks to months.

For healthcare professionals, this technology simplifies the task of administering medications at optimal therapeutic dosages, contributing to better patient outcomes.

Commitment to Innovation

Dr. Shahin Fesharaki, Lupin’s Chief Scientific Officer, emphasizes that PrecisionSphere™ highlights the company’s dedication to innovation in the pharmaceutical landscape. The platform harnesses regulatory expertise, scalable manufacturing capabilities, and adaptive collaboration models to break down barriers to LAI development. This enables partners to efficiently market advanced LAIs across numerous therapeutic areas.

The implications of this strategic program are far-reaching. By improving patient adherence to therapies and creating robust collaborations, Lupin is gearing up to meet the increasing expectations in modern healthcare. The reduction in how frequently patients must receive medications promises to contribute to greater overall health and treatment effectiveness.

About Lupin Limited

Lupin Limited is a well-established global pharmaceutical powerhouse with operations in over 100 markets. The company specializes in a plethora of pharmaceutical products, from brand formulations and generics to complex generics and active pharmaceutical ingredients. With a focus on several therapeutic areas, including respiratory, cardiovascular, diabetes, infectious diseases, gastrointestinal, central nervous system, and women's health, Lupin boasts a significant presence in India and the U.S.

With 15 state-of-the-art manufacturing facilities and 7 research centers around the globe, Lupin employs over 24,000 dedicated professionals aimed at advancing patient health through innovative solutions, including subsidiaries like Lupin Diagnostics and Lupin Digital Health.

To learn more about Lupin, visit www.lupin.com or reach out on LinkedIn. Also, explore Nanomi, Lupin's subsidiary, at www.nanomi.com.